CSL posts US$1.3b profit
September 15, 2014
COMMONWEALTH Serum
Laboratories (CSL) has posted
net profit after tax of US$1.31b
($1.44b) for the year to June, up 8%
year on year.
Revenue was US$5,504m, up 9%
year on year, the company said.
First announced in 2011 (PD 17
Aug 2011) opened in May, CSL’s
biotechnology manufacturing
facility at Broadmeadows would
house the company’s newest
immunoglobulin manufacturing
plant, currently being
commissioned, the company said.
It said bioCSL, Australia’s only
onshore manufacturer of influenza
vaccine, produced H5N1 (bird
flu) vaccine for the Australian
Government in the past financial
year and master seeds for the H7N9
influenza strain that emerged from
China in 2013.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Sep 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Sep 14